title: Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. PRISM-PLUS Investigators.
abstract: Management and prognosis of acute coronary syndromes may be influenced by the availability of catheterization facilities at admitting hospitals. Treatment effects of tirofiban were examined in a Canadian cohort of 834 patients enrolled in the Canadian Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial according to admission into hospitals without (n = 322) or with catheterization facilities (n = 512). Hospital transfers for cardiac catheterization were facilitated using preexisting networks accelerated for the purposes of the protocol. In hospitals without facilities, the relative risks for occurrence of death, infarction, or refractory ischemia among patients receiving tirofiban plus heparin compared with heparin alone were 0.52 at 7 days (p = 0.02), 0.59 at 30 days (p = 0.03), and 0.70 at 180 days (p = 0.09); and for death or infarction, 0.32 (p = 0.02), 0.46 (p = 0.04,) and 0.51 (p = 0.03), respectively. Benefit was seen regardless of transfer status, with no statistically significant interaction between treatment, hospital type, and catheterization for any end point at any time point. The incidence of Thrombolysis In Infarction defined major bleeding with respect to therapy was not significantly different between hospital types. Thus, upstream treatment with tirofiban plus heparin confers clinical benefits in unstable angina and/or non-ST-segment elevation infarction patients regardless of whether initial presentation is to a hospital without catheterization facilities or to a hospital with such facilities.
authors.affiliation: Montreal Heart Institute, Quebec, Canada. theroux@ICM.UMontreal.ca
authors.forename: P
authors.initials: P
authors.lastname: Théroux
authors.forename: J
authors.initials: J
authors.lastname: Alexander
authors.forename: J
authors.initials: J
authors.lastname: Dupuis
authors.forename: Y
authors.initials: Y
authors.lastname: Pesant
authors.forename: P
authors.initials: P
authors.lastname: Gervais
authors.forename: D
authors.initials: D
authors.lastname: Grandmont
authors.forename: S
authors.initials: S
authors.lastname: Kouz
authors.forename: P
authors.initials: P
authors.lastname: Laramée
authors.forename: T
authors.initials: T
authors.lastname: Huynh
authors.forename: E
authors.initials: E
authors.lastname: Barr
authors.forename: F L
authors.initials: FL
authors.lastname: Sax
mesh_terms: D000208:Acute Disease; D000368:Aged; D000789:Angina, Unstable / Q000188:drug therapy*; D000925:Anticoagulants / Q000627:therapeutic use; D002170:Canada; D006328:Cardiac Catheterization; D004311:Double-Blind Method; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006761:Hospitals / Q000592:standards*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D016016:Proportional Hazards Models; D011446:Prospective Studies; D016019:Survival Analysis; D013577:Syndrome; D000077466:Tirofiban; D016896:Treatment Outcome; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014443:Tyrosine; D006493:Heparin; D000077466:Tirofiban